CN116440215A - 一种治疗手足综合征的中药组合物及其制备方法和应用 - Google Patents
一种治疗手足综合征的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN116440215A CN116440215A CN202310397902.2A CN202310397902A CN116440215A CN 116440215 A CN116440215 A CN 116440215A CN 202310397902 A CN202310397902 A CN 202310397902A CN 116440215 A CN116440215 A CN 116440215A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- hand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 86
- 208000002375 Hand-Foot Syndrome Diseases 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 210000003608 fece Anatomy 0.000 claims abstract description 20
- 241000301400 Trogopterus Species 0.000 claims abstract description 19
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 17
- 241000208152 Geranium Species 0.000 claims abstract description 17
- 241001071917 Lithospermum Species 0.000 claims abstract description 17
- 244000018716 Impatiens biflora Species 0.000 claims abstract description 16
- 235000015912 Impatiens biflora Nutrition 0.000 claims abstract description 16
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 16
- 235000005155 Tanacetum balsamita Nutrition 0.000 claims abstract description 16
- 241000972673 Phellodendron amurense Species 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims description 38
- 238000002791 soaking Methods 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960004117 capecitabine Drugs 0.000 claims description 4
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 4
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 claims description 4
- 229960003982 apatinib Drugs 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 229940040145 liniment Drugs 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 34
- 238000005406 washing Methods 0.000 abstract description 18
- 238000003958 fumigation Methods 0.000 abstract description 15
- 238000002512 chemotherapy Methods 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 14
- 238000002626 targeted therapy Methods 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 5
- 230000007774 longterm Effects 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 2
- 210000002683 foot Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 206010015150 Erythema Diseases 0.000 description 13
- 206010033553 Palmar-plantar erythrodysaesthesia syndrome Diseases 0.000 description 12
- 231100000321 erythema Toxicity 0.000 description 11
- 231100000862 numbness Toxicity 0.000 description 9
- 210000003414 extremity Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 230000036642 wellbeing Effects 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 206010040844 Skin exfoliation Diseases 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000035618 desquamation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000002996 emotional effect Effects 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 241001313855 Bletilla Species 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 229940126680 traditional chinese medicines Drugs 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000032912 Local swelling Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 238000000546 chi-square test Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 208000035824 paresthesia Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 241001166194 Geranium wilfordii Species 0.000 description 3
- 241000212322 Levisticum officinale Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000001645 levisticum officinale Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 241000972672 Phellodendron Species 0.000 description 2
- 206010037569 Purulent discharge Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 206010040849 Skin fissures Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- 241000519995 Stachys sylvatica Species 0.000 description 2
- 206010067197 Tinea manuum Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000007119 pathological manifestation Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000130781 Arnebia Species 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 235000008738 Clausena lansium Nutrition 0.000 description 1
- 244000089795 Clausena lansium Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000218202 Coptis Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000037162 Ductal Breast Carcinoma Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000387101 Erodium stephanianum Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 241000725448 Geranium dahuricum Species 0.000 description 1
- 244000275701 Geranium nepalense Species 0.000 description 1
- 241000725476 Geranium sibiricum Species 0.000 description 1
- 241001270592 Geranium tuberosum Species 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010033474 Pain of skin Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241001079007 Phellodendron chinense Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 241001300193 Speranskia Species 0.000 description 1
- 241000434639 Speranskia tuberculata Species 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000020796 long term synaptic depression Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- -1 patches Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Animal Husbandry (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种治疗手足综合征的中药组合物及其制备方法和应用。按重量份数计,所述中药组合物包括黄连5‑50份,黄柏5‑50份,川芎10‑30份,白及30‑60份,紫草10‑30份,五灵脂10‑30份,蜂房5‑10份,老鹳草10‑30份,透骨草10‑30份。本发明提供的中药组合物根据中医药理论进行中药组方筛选,配方严谨,针对化疗或靶向治疗所致的手足综合征的患者,起到清热解毒、减轻疼痛等作用,提高患者生活质量,并且其副作用较小,制备简单,使用方便,取材简单,价格低廉,适合患者长期外用熏洗。
Description
技术领域
本发明属于中医药技术领域,具体包含一种治疗手足综合征的中药组合物及其制备方法和应用。
背景技术
抗肿瘤治疗后易出现手足皮肤发黑、破溃、流脓、疼痛等手足表现,称为手足综合征(hand-foot syndrome,HFS)或手足皮肤反应(hand-foot skin reaction,HFSR),发生率分别是6%-64%和9%-62%,在大多数文献中未将二者做明确区分,统称为手足综合征。手足综合征虽不会危及患者的生命,但是严重影响患者的生活质量,严重的手足综合征生活难以自理,另外可能会因严重的手足综合征导致化疗剂量减量甚至需要停止治疗,进而影响肿瘤的治疗。目前没有统一的治疗方案,西医采用大剂量维生素B6,COX-2抑制剂塞来昔布、糖皮质激素、尿素乳膏等治疗,但疗效不佳。
从古至今,已有大量的中医药用于手足皮肤破损的诊治,虽与现代诊断不同,但其临床表现有相同之处,现将古典书籍中类似手足综合征的相关诊治总结归纳,并应用于临床治疗中,取得了较好的效果,手足皮肤不良反应相当于中医“浸淫疮”、“指疔”、“鹅掌风”、“瘑疮”。《医宗金鉴》中记载“瘑疮生于指掌之中,形如茱萸,两手相对而生。亦有成攒者,起黄白脓疱,痒痛无时,破津黄汁水,时好时发,极其疲顽,由风湿客于肤腠而成”,“鹅掌风初起紫白斑点,叠起白皮,坚硬且厚,干枯燥裂,延及遍手”。中医认为化疗药物属大毒之品,既伤及脾胃,又耗伤气血,卫气不固,外感风寒湿等邪气,邪聚于局部,气血凝滞,故手足麻木,感觉迟钝,瘀滞较甚者,可见皮肤色黑,瘀久化热,化毒,毒热瘀滞,不通则痛,甚至伴有疼痛,肿胀,红斑,脱屑,皲裂等严重皮肤毒性反应。可采用内服、外洗浸泡、软膏等治疗,手足为肢体远端,外洗浸泡,软膏涂擦等方式可直达病所,可以起到较好的治疗效果。大量临床病例显示,中药在治疗因化疗或靶向治疗导致的手足综合征、提高患者生活质量等方面均发挥着积极的作用。
为进一步扩大可有效治疗因化疗或靶向治疗导致的手足综合征的中药组方,特提出本发明的技术方案。
发明内容
鉴于现有技术中存在的上述问题,本发明的第一个目的在于提供一种治疗手足综合征的中药组合物。该中药组合物可治疗因化疗或靶向治疗所致的手足综合征,起到清热解毒、减轻疼痛等作用,可有效提高患者生活质量。
本发明的第二个目的在于提供一种制备如上所述中药组合物的方法。
本发明的第三个目的在于提供一种治疗手足综合征的中药制剂。
本发明的第四个目的在于提供一种利用如上所述的中药组合物或中药制剂在制备治疗手足综合征的药物中的应用。
为实现以上第一个目的,本发明所采用的技术方案包括:
本发明公开一种治疗手足综合征的中药组合物,按重量份数计,包括黄连5-50份,黄柏5-50份,川芎10-30份,白及30-60份,紫草10-30份,五灵脂10-30份,蜂房5-10份,老鹳草10-30份,透骨草10-30份。
本发明提供的中药组合物根据中医药理论进行中药组方筛选,配方严谨,针对化疗或靶向治疗出现手足综合征的患者,具有清热解毒、减轻疼痛等作用,可有效提高患者生活质量,并且其副作用较小,制备简单,使用方便,取材简单,价格低廉,适合患者长期外用熏洗。
本发明配方种所采用的药材的来源及功能主治如下:
黄连:属多年生草本植物,味苦性寒,入心、肝、胃、大肠经,清热泻火,燥湿,解毒,主治热病邪入心经之高热,烦躁,谵妄或热盛迫血妄行之吐血,湿热胸痞等。
黄柏:为芸香科植物黄皮树Phellodendron chinense Schneid.的干燥树皮,味苦性寒,入肾、膀胱经,清热泻火,燥湿解毒。主治热痢、泄泻、消渴、黄疸等。
川芎:味辛性温,归肝胆、心包经。活血祛瘀,行气开郁、祛风止痛,主治月经不调、经闭痛经等。
白及:是兰科、白及属地生草本植物,味苦甘,凉,入肺经。补肺,止血,消肿,生肌,敛疮。治肺伤咳血,衄血,金疮出血,痈疽肿毒,溃疡疼痛,汤火灼伤,手足皲裂。
紫草:是紫草科紫草属多年生草本植物,味苦、寒,入心包经、肝经。凉血,活血,清热,解毒。治温热斑疹,湿热黄疸,紫癜,吐、衄、尿血,淋浊,热结便秘,烧伤,湿疹,丹毒,痈疡。
五灵脂:为鼯鼠科动物橙足鼯鼠和飞鼠等的干燥粪便,味甘、温,入肝、脾经。生用行血止痛。治心腹血气诸痛,妇女经闭,产后瘀血作痛;外治蛇、蝎、蜈蚣咬伤。炒用止血。治妇女血崩,经水过多,赤带不绝。
露蜂房:为胡蜂科昆虫黄星长脚黄蜂或多种近缘昆虫的巢,味甘,平,有毒,入肺、肝经。祛风,攻毒,杀虫。治惊痫,风痹,瘾疹瘙痒,乳痈,疔毒,瘰疬,痔漏,风火牙痛,头癣,蜂螫肿疼。
老鹳草:为牻牛儿苗科植物牻牛儿苗Erodium stephanianum Willd.、老鹳草Geranium wilfordii Maxim.、西伯利亚老鹳草Geranium sibiricum L.、尼泊尔老鹳草Geranium nepalense Sweet、块根老鹳草Geranium dahuricum DC.带果实的全草;具有祛风通络,活血,清热利湿等功效;常用于风湿痹痛,肌肤麻木,筋骨酸楚,跌打损伤,泄泻,痢疾,疮毒等。
透骨草:是多年生草本植物,味辛、温,入肺、肝经。祛风除湿;舒筋活血;散瘀消肿;解毒目痛。主风湿痹痛;筋骨挛缩;寒湿脚气;腰部扭伤;瘫痪;闭经;阴囊湿疹;疮疖肿毒。
手足皮肤不良反应相当于中医“浸淫疮”、“指疔”、“鹅掌风”、“瘑疮”。《医宗金鉴》中记载“瘑疮生于指掌之中,形如茱萸,两手相对而生。亦有成攒者,起黄白脓疱,痒痛无时,破津黄汁水,时好时发,极其疲顽,由风湿客于肤腠而成”,“鹅掌风初起紫白斑点,叠起白皮,坚硬且厚,干枯燥裂,延及遍手”。可采用内服、外洗浸泡、软膏等治疗,手足为肢体远端,外洗浸泡,软膏涂擦等方式可直达病所,起到较好的治疗效果。
化疗药物属于“药毒”范畴,具有大毒,耗伤气血,损伤脾胃,气血生化不足,手足为四肢末端,微循环、血运比较少,药毒聚于局部,或是化疗药物伤及气血,气虚血瘀,最终导致气滞血瘀,血不养荣,早期可见手足皮肤色紫暗,感觉迟钝、麻木,晚期可见皮肤皲裂、脱屑等。药毒聚于局部,不通则痛,日久郁而化热,化毒,伤及肌肤,可见皮肤红斑,疼痛,严重者可出现皮肤破裂,渗出较明显。
化疗期间患者出现手足皮肤发红,红斑,水肿,疼痛,破溃,渗出明显,为湿热热毒之征,药用黄连,黄柏清热祛湿、解毒或化疗早期或者后期出现手足皮肤干燥、粗糙、皲裂、脱屑,感觉迟钝、麻木感等,为血虚风燥之征,药用白及收敛生肌,共为君药,川芎行气活血,配伍五灵脂活血,可活血通络,又可止痛,共为臣药。手足皮肤红斑、疼痛、肿胀,皮肤角化过度,可伴有皲裂、脱屑或者感觉异常,麻刺感、烧灼感,为瘀毒阻滞之征,药用透骨草、老鹳草,共为佐药,与川芎、五灵脂活血通络止痛。蜂房养血祛风,配伍紫草清热凉血、解毒,共为使药,既可养血润肤,又可凉血解毒。
进一步,按重量份数计,所述中药组合物包括黄连5-30份,黄柏5-30份,川芎10-30份,白及30-60份,紫草10-30份,五灵脂10-30份,蜂房5-10份,老鹳草10-30份,透骨草10-30份。
进一步,按重量份数计,所述中药组合物包括黄连10份,黄柏10份,川芎20份,白及30份,紫草30份,五灵脂30份,蜂房5份,老鹳草30份,透骨草30份。
进一步,按重量份数计,所述中药组合物包括黄连5份,黄柏5份,川芎30份,白及30份,紫草30份,五灵脂10份,老鹳草30份,蜂房10份,透骨草30份。
进一步,按重量份数计,所述中药组合物包括黄柏50份,老鹳草30份,黄连50份,蜂房10份,五灵脂10份,紫草30份,川芎30份,白及30份,透骨草10份。
为实现以上第二个目的,本发明所采用的技术方案包括:
本发明公开一种制备如上所述的中药组合物的方法,包括如下步骤:
按质量份数称取各原料,加水浸没,浸泡30-40分钟,煎煮两次;
其中,第一煎武火烧开以后,文火煮30-50分钟;第二煎武火烧开以后,文火煮20-40分钟,煎煮去渣取汁后,即得。
为实现以上第三个目的,本发明所采用的技术方案包括:
本发明公开一种治疗手足综合征的中药制剂,将如上所述的中药组合物制成外用药物。
进一步,所述外用药物的剂型包括但不限于膏剂、搽剂、洗剂、贴剂、糊剂、凝胶剂、涂膜剂或巴布剂。
为实现以上第四个目的,本发明所采用的技术方案包括:
本发明公开一种利用如上所述的中药组合物或如上所述的中药制剂在制备治疗手足综合征的药物中的应用。
在一个具体实施方式中,制备成洗剂来熏洗治疗手足综合征,具体步骤为:
按质量份数称取各原料,加水浸没,浸泡30-40分钟,煎煮两次;
其中,第一煎武火烧开以后,文火煮40分钟;第二煎武火烧开以后,文火煮30分钟,煎煮去渣取汁后,取合适的距离先熏蒸,待药液温度降至患者可耐受程度时(水温约35-40℃),将患处浸入药液中泡洗,每次熏洗30min,每日1次。
进一步,所述手足综合征为因化疗药物或靶向药物所致的手足综合征。
进一步,所述化疗药物选自嘧啶类似物如卡培他滨、5-氟尿嘧啶等,或是蒽环类药物如多柔比星等。
进一步,所述靶向药物包括但不限于阿帕替尼、索拉非尼或舒尼替尼。
本发明有益效果:
本发明公开一种治疗手足综合征的中药组合物,较现有技术中公开的组方具有如下优势:
1、本发明公开的中药组合物,针对化疗或靶向治疗引起手足综合征的患者,可起到清热解毒、减轻疼痛等作用,可有效提高患者生活质量,并且其副作用较小,制备简单,外用熏洗方便,取材简单,价格低廉,适合患者长期外用熏洗。
2、本发明根据中医药理论进行中药组方筛选,提供的治疗手足综合征的中药组合物配比科学合理,本发明提供的中药组合物具有热解毒、减轻疼痛等不适的作用、提高患者生活质量的作用;经长期临床实验研究表明,本发明提供的治疗手足综合征的中药组合物安全性高,毒副作用低。
3、本发明提供的治疗手足综合征的中药组合物,可以方便和药学载体制备成汤剂外用熏洗,临床上使用方便。
附图说明
图1示出典型病例1在治疗前后的对比图。
图2示出典型病例2在治疗前后的对比图。
具体实施方式
为了更清楚地说明本发明,下面结合优选实施例对本发明做进一步的说明。应当明确,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其它实施例,都属于本发明保护的范围。
实施例1
按重量份数计,所述配方为:黄连10份,黄柏10份,川芎20份,白及30份,紫草30份,五灵脂30份,蜂房5份,老鹳草30份,透骨草30份;
按照方剂称取各原料,加水浸没,浸泡30-40分钟,煎煮两次;其中,第一煎武火烧开以后,文火煮40分钟;第二煎武火烧开以后,文火煮30分钟,煎煮去渣取汁后,即得汤剂外用熏洗。
实施例2
按重量份数计,所述配方为:黄连5份,黄柏5份,川芎30份,白及30份,紫草30份,五灵脂10份,老鹳草30份,蜂房10份,透骨草30份;
按照方剂称取各原料,加水浸没,浸泡30-40分钟,煎煮两次;其中,第一煎武火烧开以后,文火煮40分钟;第二煎武火烧开以后,文火煮30分钟,煎煮去渣取汁后,即得汤剂外用熏洗。
实施例3
按重量份数计,所述配方为:黄柏50份,老鹳草30份,黄连50份,蜂房10份,五灵脂10份,紫草30份,川芎30份,白及30份,透骨草10份;
按照方剂称取各原料,加水浸没,浸泡30-40分钟,煎煮两次;其中,第一煎武火烧开以后,文火煮40分钟;第二煎武火烧开以后,文火煮30分钟,煎煮去渣取汁后,即得汤剂外用熏洗。
典型病例
病例1:许某,女,60岁,2021年3月于北京妇产医院行宫腔镜下子宫内膜刮宫,病理示:(宫内占位、宫内占位基底部)腺癌,中-低分化,考虑为子宫内膜样癌,IHC:ER(+)PR(-)Ki-67(+70%)MLH(+)MSH(+)MSH6(+),考虑浆液性癌可能性大。2021年5月18日行全子宫双附件切除术,术后病理不详。术后予紫杉醇联合卡铂化疗1次,因手脚麻木改为多柔比星联合奥沙利铂治疗中。2021年7月27日初诊刻下症:手脚麻木,疼痛,活力不利,左足痛甚,左足皮肤破溃,流脓,口苦,口干,乏力,纳差,眠可,大便干,小便调。
采用如下配方进行治疗:黄柏50g,老鹳草30g,黄连50g,蜂房10g,五灵脂10g,紫草30g,川芎30g,白及30g,透骨草10g。
用法:按照实施例1的煎煮方法进行制备,加水煎煮药物至1000毫升,合适的距离先熏蒸,待药液温度降至患者可耐受程度时(水温约35~40℃),再将四肢浸入药液中泡洗,每次熏洗30min,每日1次,14天为一疗程。治疗前后的对比图参见图1,说明本组方可以有效改善因化疗药物所致的手足综合征。
病例2:潘某,女,52岁,2013年9月于北京航天总医院行乳腺肿物穿刺,病理示:左乳浸润性导管癌,部分呈浸润性小叶癌,IHC:ER(+++)PR(+++)Ki-67(<5%)Her-2(+),行TAC化疗方案4次。2013年12月行左乳改良根治术,术后病理:浸润性导管癌,累及皮肤和乳头,淋巴结转移(2/2),术后行TAC化疗方案2次。化疗结束后口服来曲唑治疗,后因关节疼痛改为依西美坦。2017年6月复查左腋下淋巴结、胸椎转移可能转移,遂行淋巴结穿刺:ER(+++)PR(-)Ki-67(+20%)Her-2(++),FISH(-),予表柔比星化疗4次,化疗结束后口服阿那曲唑治疗。2018年3月骨转移控制不佳,内分泌治疗药物改为氟维司群治疗。2019年1月CT示:肺部多发小结节,不除外转移。北京肿瘤医院病理会诊:(左乳穿刺)浸润性导管癌,II级,IHC:ER(+90%)PR(+80%)Her-2(0)Ki-67(+10%),淋巴结穿刺:ER(+90%)PR(-)Her-2(2+)Ki-67(+20%),予多西他赛化疗8周期,病灶缩小。内分泌药物改为口服托瑞米芬。2020年6月因出现胸水予白蛋白紫衫醇化疗3周期,肿瘤控制不佳。2020年9月开始安罗替尼联合卡培他滨治疗。2021年11月23日初诊刻下症:双手麻木,皮肤干裂,脱屑,疼痛,胃胀,眠可,二便调。
采用如下配方进行治疗:黄连5份,黄柏5份,川芎30g,白及30g,紫草30g,五灵脂10g,老鹳草30g,蜂房10g,透骨草30g。
用法:按照实施例1的煎煮方法进行制备,加水煎煮药物至1000毫升,合适的距离先熏蒸,待药液温度降至患者可耐受程度时(水温约35~40℃),再将四肢浸入药液中泡洗,每次熏洗30min,每日1次,14天为一疗程。治疗前后的对比图参见图2,说明本组方可以有效改善因化疗药物所致的手足综合征。
临床试验
1研究对象
1.1病例来源
病例来源于2020年9月至2022年3月就诊于广安门医院肿瘤科门诊及住院患者,符合西医诊断标准确诊为手足综合征,本研究设计总样本量60例,其中试验组30例,对照组30例,采用随机数字表法,将随机数字及对应干预方案放入密封、不透光的信封中,信封外贴上编号,研究者按照编号的顺序将信封打开,将患者随机分为试验组与对照组。
1.2诊断标准
1.2.1手足皮肤不良反应的临床表现
手足皮肤不良反应包括手足综合征和手足皮肤反应。手足综合征最初表现为手掌和脚掌感觉迟钝、麻木,然后可进展为刺痛和灼痛,局部可见红斑和水肿,病变多在手指远端脂肪垫的外侧,或伴有指甲改变。局部红斑可发展为水疱,继而脱屑、糜烂、溃疡。反复发作的手足综合征可导致类似角化病的掌跖角质层肥厚。手足皮肤反应的特点:红斑有或无水泡,继而手掌足底角化过度损伤同时感觉异常或感觉迟钝,多出现在手足的弯曲、负重或受压部位,光泽、指纹消失不多见,亚裔发生率更高。
1.2.1手足综合征分级标准
分级标准参照NCI标准:①0级:无临床表现;②1级:轻微的皮肤改变或皮炎(如红斑、脱屑)伴感觉异常(如麻木感、针刺感、烧灼感),但不影响日常活动;③2级:如前皮肤改变伴疼痛,轻度影响日常活动,皮肤表面完整;④3级:溃疡性皮炎或皮肤改变伴剧烈疼痛,严重影响日常生活,明显组织破坏(如脱屑、水疱、出血、水肿)。
1.3纳入标准
①卡培他滨等化疗或阿帕替尼等靶向治疗后出现手足综合征;②KPS评分≥60分;③年龄18-75岁;④无智力及精神障碍,语言表达能力正常,对自身疼痛及一般状况有判断能力,且能合作评价疼痛及生活质量内容等;⑤了解并同意接受该项治疗,并签署知情同意书。
1.4排除标准
①具有其他部位严重疼痛的危症病人;②皮肤过敏性疾病患者;③无法配合临床试验的患者。
2治疗方案
将符合纳排标准的患者随机分成试验组和对照组,试验组予中药熏洗治疗,选用实施例2的配方,按制备步骤加水煎煮至1000mL,取合适的距离先熏蒸,待药液温度降至患者可耐受程度时(水温约35~40℃),再将四肢浸入药液中泡洗,每次熏洗30min,每日1次,14天为1个观察周期。对照组采用凡士林外涂。以上试验用药均由中国中医科学院广安门医院药学部制剂室提供。
3观察指标
3.1观察分析两组治疗疗效:疗效评价标准:治愈(CR):患者治疗后红斑、疼痛以及手足皮肤红肿等多种临床症状及体征均彻底消除,且分级降至0级;有效(PR):患者治疗后红斑、疼痛以及手足皮肤红肿等多种临床症状及体征均得到一定程度缓解,且分级下降1级及以上;无效(NP):患者治疗后红斑、疼痛以及手足皮肤红肿等多种临床症状及体征均未存在任何变化且分级无下降。其中,总有效率=治愈率+有效率。
3.2生活质量评价:采用生命质量量表(the Functional Assessment of CancerTherapy breast cancer-specific,FACT-B)对乳腺癌患者而的生活质量进行评价。FACT是Cell等研制的癌症治疗功能评价系统,由测量癌症病人生命质量共性部分的一般量表(共性模块FACI-G)和特定癌种的特异量表(特异模块)构成。FACT-G由27个条目构成,分为四个部分,即生理状况(physical well-being)、情感状况(emotional well-being)和社会/家庭状况(social/family well-being)功能状况(functional well-being)。FACT-B是由FACT-G和乳腺癌的特异模块组成,每个条目均采用等级式条目设置(0-4)。得分越高表示生命质量越好。
3.3中医证候评分:参考《中药新药临床研究指导原则》,评定治疗前后患者的皮肤感觉、肢体受累、皮肤改变、疼痛情况等证候,积分越低,患者证候改善越理想。中医证候评分分为主症和次证,主症包括肌肤甲错、肌肤皮疹形态、手足麻木、感觉异常、疼痛,次要症状包括面色、头晕目眩、神疲乏力、舌苔、脉象。
3.4安全性指标:治疗前、后查血常规、肝肾功、尿常规、便常规、心电图。
4统计学方法
采用SPSS26.0数据统计软件对临床数据进行分析整理,采用描述性统计对所有数据进行分析,包括人口统计学资料、基线、各项疗效评估指标等。针对计量资料,进行正态分布检验,符合正态分布的数据用独立样本t检验,描述其均数、标准差、中位数、最大值和最小值;不符合正态分布的数据采用非参数秩和检验。针对计数资料,采用卡方检验,描述其频数和百分比,P<0.05为统计学上有显著差异。
5结果
5.1入组病例情况
共入组60例,其中试验组入组30例,对照组入组30例。试验组年龄(50.30±1.586)岁;对照组年龄(49.80±1.774)岁,两组病例的年龄经独立样本t检验,组间差异无统计学意义。肿瘤大小、组织学分级、肿瘤分期等一般资料经卡方检验、独立样本t检验,组间差异均无统计学意义(P>0.05),具有可比性。
5.2HFS分级变化及疗效分析
试验组在入组时HFS 1级1例、2级17例、3级12例,对照组在入组时1级2例、2级15例、3级13例,经卡方检验,两组间差异无统计学意义(表1),试验组治疗后0级16例、1级9例、2级3例、3级2例;对照组治疗后0级8例、1级7例、2级7例、3级8例。经卡方检验,组间差异有统计学意义(P=0.044)(表2)。
表1治疗前两组HFS分级比较(例)
表2治疗后两组HFS分级比较(例)
HFS疗效分析:试验组治愈16例(53.33%)、有效12例(40%)、无效2例(6.67%),总有效率为93.33%;对照组治愈8例(26.67%)、有效14例(46.67%)、无效8例(26.66%),总有效率为73.34%,经卡方检验,组间差异有统计学意义(P<0.05)。
5.3生活质量评分前后对比
两组患者治疗前生理状况、社会家庭状况、情感状况、功能状况、附加关注各项评分均无差异(P>0.05)。治疗后,与对照组相比,FACT-B中生理状况、社会家庭状况、情感状况、功能状况、附加关注各项评分均升高,差异具有统计学意义(P<0.05),具体如表3-4所示。
表3FACT-B各项治疗前评分比较(分)
注:生理状况、社会/家庭状况、情感状况、功能状况、附加关注,经检验,与治疗前比较,*P>0.05,无统计学意义。
表4FACT-B各项治疗后评分比较(分)
注:生理状况、社会/家庭状况、情感状况、功能状况、附加关注,经非参数检验,与治疗前比较,*P<0.05,有统计学意义。
5.4中医证候评分前后对比
经正态性检验,中医证候主症、次证、总分评分不符合正态分布。经非参数检验,试验组和对照组在治疗前两组间主症、次证、总分差异无统计学差异(P>0.05);经治疗后,试验组和对照组治疗后两组间主症、次证、总分差异有统计学差异(P=0.011)(表5)。
表5中医证候评分治疗前后比较(分)([M(P25,P75)])
5.5安全性分析
不良事件
试验过程中,试验组与对照组未发生不良事件。两组均未发生严重不良事件。
显然,本发明的上述实施例仅仅是为清楚地说明本发明所作的举例,而并非是对本发明的实施方式的限定,对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动,这里无法对所有的实施方式予以穷举,凡是属于本发明的技术方案所引伸出的显而易见的变化或变动仍处于本发明的保护范围之列。
Claims (10)
1.一种治疗手足综合征的中药组合物,其特征在于,按重量份数计,包括黄连5-50份,黄柏5-50份,川芎10-30份,白及30-60份,紫草10-30份,五灵脂10-30份,蜂房5-10份,老鹳草10-30份,透骨草10-30份。
2.根据权利要求1所述的中药组合物,其特征在于,按重量份数计,包括黄连5-30份,黄柏5-30份,川芎10-30份,白及30-60份,紫草10-30份,五灵脂10-30份,蜂房5-10份,老鹳草10-30份,透骨草10-30份。
3.根据权利要求1所述的中药组合物,其特征在于,按重量份数计,包括黄连10份,黄柏10份,川芎20份,白及30份,紫草30份,五灵脂30份,蜂房5份,老鹳草30份,透骨草30份。
4.根据权利要求1所述的中药组合物,其特征在于,按重量份数计,包括黄连5份,黄柏5份,川芎30份,白及30份,紫草30份,五灵脂10份,老鹳草30份,蜂房10份,透骨草30份。
5.根据权利要求1所述的中药组合物,其特征在于,按重量份数计,包括黄柏50份,老鹳草30份,黄连50份,蜂房10份,五灵脂10份,紫草30份,川芎30份,白及30份,透骨草10份。
6.如权利要求1-5任一项所述的中药组合物的制备方法,其特征在于,包括如下步骤:
按重量份数称取各原料,加水浸没,浸泡30-40分钟,煎煮两次;
其中,第一煎武火烧开以后,文火煮30-50分钟;第二煎武火烧开以后,文火煮20-40分钟,煎煮去渣取汁后,即得。
7.一种治疗手足综合征的中药制剂,其特征在于,将权利要求1-5任一项所述的中药组合物制成外用药物;
优选地,所述外用药物的剂型包括膏剂、搽剂、洗剂、贴剂、糊剂、凝胶剂、涂膜剂或巴布剂。
8.如权利要求1-5任一所述的中药组合物或如权利要求7所述的中药制剂在制备治疗手足综合征的药物中的应用。
9.根据权利要求8所述的应用,其特征在于,所述手足综合征为因化疗药物或靶向药物所致的手足综合征。
10.根据权利要求9所述的应用,其特征在于,所述化疗药物选自卡培他滨、5-氟尿嘧啶或多柔比星;
优选地,所述靶向药物选自阿帕替尼、索拉非尼或舒尼替尼。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310397902.2A CN116440215A (zh) | 2023-04-13 | 2023-04-13 | 一种治疗手足综合征的中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310397902.2A CN116440215A (zh) | 2023-04-13 | 2023-04-13 | 一种治疗手足综合征的中药组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116440215A true CN116440215A (zh) | 2023-07-18 |
Family
ID=87119703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310397902.2A Pending CN116440215A (zh) | 2023-04-13 | 2023-04-13 | 一种治疗手足综合征的中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116440215A (zh) |
-
2023
- 2023-04-13 CN CN202310397902.2A patent/CN116440215A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103721131B (zh) | 一种治疗妇女慢性盆腔炎的中药栓剂及其制备方法 | |
CN110478452B (zh) | 一种治疗痛风的中药组合物及其制备方法 | |
CN116688017A (zh) | 一种具有银屑病治疗功效的蓝萼香茶菜复方软膏及其制备方法 | |
CN103083592B (zh) | 一种治疗痛风性关节炎的中药 | |
CN104815318A (zh) | 一种治疗痛风的中药制剂 | |
CN115252691B (zh) | 一种用于治疗气滞血瘀型冠心病心绞痛的中药组合物 | |
CN117599125A (zh) | 一种用于治疗骨质疏松症的补钙壮骨中药组合物及制法和应用 | |
CN113768978B (zh) | 一种治疗溃疡性结肠炎的彝药组合物及其制备方法 | |
CN116440215A (zh) | 一种治疗手足综合征的中药组合物及其制备方法和应用 | |
CN114632128A (zh) | 通络化浊方及使用方法 | |
CN110051803B (zh) | 治疗寻常型银屑病的药物组合物、制剂及其制法应用 | |
CN107007702A (zh) | 一种治疗骨关节病的中药组合物及其制剂 | |
CN106511838A (zh) | 一种治疗酒精性肝损伤的中药颗粒 | |
CN105233078A (zh) | 一种用于治疗病毒性肝炎的中药组合物 | |
CN112138084A (zh) | 一种治疗支气管扩张症气阴两虚、痰热壅肺证的中药方及其应用 | |
CN114504619B (zh) | 一种治疗特应性皮炎的中药组合物 | |
CN103028045A (zh) | 用于治疗急性湿疹的外用中药组合物及其制备方法 | |
CN103920010A (zh) | 具有止血止痛及抗炎作用的药物组合物及其制备方法和用途 | |
CN115105576B (zh) | 一种治疗卵巢癌的中药组合物及其中药制剂和应用 | |
CN113144080B (zh) | 一种治疗冠状动脉硬化斑块的中药 | |
CN115581749B (zh) | 一种治疗乳腺增生症的中药组合物及其制备方法 | |
CN110496199B (zh) | 一种治疗牛皮癣的药物及其制备方法 | |
CN115252731B (zh) | 一种用于治疗湿疹的中药组合物及其制备方法和应用 | |
CN106266152A (zh) | 一种治疗湿疹的药物组合物及其制备方法和用途 | |
CN110302271B (zh) | 黄栀祛伤水及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |